Dengue virus serotype 2 antigens (DENV-2 antigens)

Dengue virus serotype 2 (DENV-2) antigens refer to the structural and non-structural proteins encoded by the DENV-2 genome, which serve as the primary targets for the host immune system and therapeutic development [1, 6]. The viral polyprotein is processed into ten distinct proteins: three structural proteins (Capsid, Pre-membrane, and Envelope) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) [3, 12]. The Envelope (E) protein is the major surface component responsible for host cell receptor binding and membrane fusion, making it the principal target for neutralizing antibodies and vaccine design [8, 13, 14]. Non-structural proteins such as NS3 and NS5 possess essential enzymatic activities for viral RNA replication and are targets for experimental small-molecule antivirals [1, 12]. DENV-2 is clinically significant due to its frequent association with severe disease outcomes, including dengue hemorrhagic fever and dengue shock syndrome [15, 19, 20]. A major challenge in targeting these antigens is antibody-dependent enhancement (ADE), where sub-neutralizing antibodies can facilitate viral entry into immune cells, potentially exacerbating the infection [11, 13].

Other names

DENV-2 proteinsDengue virus type 2 polyproteinDENV-2 structural and non-structural proteinsDengue virus serotype 2 viral proteins

Vaccines like Qdenga and Dengvaxia utilize live-attenuated or chimeric viruses to present DENV-2 antigens, primarily the Envelope (E) and Pre-membrane (prM) proteins, to the host immune system to induce neutralizing antibodies and T-cell responses [6, 10, 11]. Therapeutic monoclonal antibodies, such as 2D22, bind to specific quaternary epitopes on the E protein to neutralize the virus and prevent host cell entry [8, 13]. Experimental antiviral agents target the enzymatic activities of non-structural proteins, including the NS3 protease/helicase and NS5 RNA-dependent RNA polymerase, to inhibit the viral replication cycle [12, 14].